Clinical Trial

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

Study acronym: RAD202
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-07; most recent amendment 2026-02-08.
Status change: Not Yet Recruiting → Recruiting 2025-03-05
Trial Details
NCT Number NCT06824155
Lead Sponsor Radiopharm Theranostics, Ltd
Conditions HER2 Gene Mutation, Advanced Solid Tumors
Enrollment 30 participants
Start Date 2025-02-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11